MDMA for PTSD: FDA Advisory Panel Vote and Future Implications

The chapter analyzes the recent FDA advisory panel vote against the use of MDMA for treating post-traumatic stress disorder, focusing on the flaws in the trial design rather than the potential of MDMA therapy. It discusses concerns raised about biases in patient selection, lack of blinding, and insufficient data collection, alongside allegations of data suppression and negative experiences of trial participants. The chapter also explores the implications of the FDA's decision on the field of psychedelic treatments for psychiatric illnesses and how companies like Compass Pathways and MindMed are adapting their trial designs based on FDA feedback.